Inclusion Criteria:  Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.  - somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.  Patients who are willing to provide written informed consent.  Exclusion Criteria:  1. Patients with contraindication according to prescribing information for Lutathera in Korea.